Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Head and Neck Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Tongue Neoplasms 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Oropharyngeal Neoplasms 1Nasopharyngeal Neoplasms 1Mouth Neoplasms 1Lung Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Radiosurgery 12Temozolomide 10Radiotherapy 10Magnetic Resonance Spectroscopy 7Erlotinib Hydrochloride 6Bevacizumab 6Surgical Procedures, Operative 5Pemetrexed 5Gefitinib 5Drug Therapy 5Carboplatin 5pyrotinib 4icotinib 4aumolertinib 4Trastuzumab 3Spermine Synthase 3Radiation 3Lomustine 3Etoposide 3Dexmedetomidine 3Chlorotoxin 3Carmustine 3osimertinib 2camrelizumab 2apatinib 2Tyrosine Kinase Inhibitors 2Thiotepa 2Surveys and Questionnaires 2Sevoflurane 2Propofol 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Brain Neoplasms × 5-fluoropentyl-2-methylmalonic acid × Clear all
NCT00805636 2010-05-12

Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.

Aposense Ltd.

Phase 2 Unknown
30 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡